Indomethacin vs Diclofenac for Preventing PEP

Recruiting N/A Interventional Study
ERCP Pancreatitis Non-steroidal Anti-inflammatory (NSAID) Indomethacin Diclofenac
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 90
Sex
Any
Study type
Interventional
Purpose
Prevention
Participants needed
4,050 (estimated)
Sponsor
Air Force Military Medical University, China · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Pancreatitis is the most common and serious complication following post-endoscopic retrograde cholangiopancreatography (ERCP) and is associated with occasional mortality, extended hospital stays, and increased healthcare expenses. Preprocedural administration of rectal non-steroidal anti-inflammatory drugs (NSAIDs) was demonstrated to be an effective and convenient strategy for post-ERCP pancreati…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * 18-90 years old patients with native papilla who planned to undergo ERCP Exclusion Criteria: * Previous biliary sphincterotomy and papillary large balloon dilation * Planned for placements of pancreatic duct stents (eg. pancreatic duct strictures, planned ampullectomy) * All…
Contacts

Yanglin Pan, MD

86-84771536

yanglinpan@hotmail.com

CONTACT